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Abstract
Background: Schizophrenia, bipolar disorder, and major depression are devastating mental diseases, each with
distinctive yet overlapping epidemiologic characteristics. Microarray and proteomics data have revealed genes
which expressed abnormally in patients. Several single nucleotide polymorphisms (SNPs) and mutations are
associated with one or more of the three diseases. Nevertheless, there are few studies on the interactions among
the disease-associated genes and proteins.
Results: This study, for the first time, incorporated microarray and protein-protein interaction (PPI) databases to
construct the PPI network of abnormally expressed genes in postmortem brain samples of schizophrenia, bipolar
disorder, and major depression patients. The samples were collected from Brodmann area (BA) 10 of the prefrontal
cortex. Abnormally expressed disease genes were selected by t-tests comparing the disease and control samples.
These genes were involved in housekeeping functions (e.g. translation, transcription, energy conversion, and
metabolism), in brain specific functions (e.g. signal transduction, neuron cell differentiation, and cytoskeleton), or in
stress responses (e.g. heat shocks and biotic stress).
The diseases were interconnected through several “switchboard”-like nodes in the PPI network or shared abnormally
expressed genes. A “core” functional module which consisted of a tightly knitted sub-network of clique-5 and -4s was
also observed. These cliques were formed by 12 genes highly expressed in both disease and control samples.
Conclusions: Several previously unidentified disease marker genes and drug targets, such as SBNO2 (schizophrenia),
SEC24C (bipolar disorder), and SRRT (major depression), were identified based on statistical and topological analyses of
the PPI network. The shared or interconnecting marker genes may explain the shared symptoms of the studied
diseases. Furthermore, the “switchboard” genes, such as APP, UBC, and YWHAZ, are proposed as potential targets for
developing new treatments due to their functional and topological significance.
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Schizophrenia, bipolar disorder, and major depression are
suffered by approximately 1%, 5% or 20%, respectively, of
human during their life time. Improving the diagnoses
and treatments of these devastating diseases is an impor-
tant task. However, few studies of mental diseases have
used post-mortem brain samples [1]. Researchers did not
have convenient access to brain samples of psychiatric
patients until 1994 when the Stanley Brain Collection
started.
These three diseases each have distinct characteristics,
but they also share a few symptoms. All diseases above
may show signs of psychosis, and in which both bipolar
disorder and major depression have depressive symptoms.
The shared symptoms suggest related disease mechanisms.
These diseases have always been affiliated with neuron and
dopamine abnormalities [2-9]. Abnormalities in the glia,
GABA, and other neurotransmitter systems were revealed
in more recent studies using patients’ brain samples from
the Stanley Brain Collections [10-15]. The genetics of
these diseases are overlapped [16,17]. Related single
nucleotide polymorphisms (SNPs) and mutations, such as
coding variants in the lipid transporter ABCA13, are often
associated with more than one of the three diseases [1,2].
Microarrays of frontal, prefrontal, cingulate, and cerebellar
cortex samples show disruption of mRNA or protein
expression in intracellular signalling, synaptic neurotrans-
mission, oligodendrocyte, stress responses, cytoskeleton,
ATP biosynthesis, and translation [18-35].
The data of human protein-protein interactions (PPIs)
brought insights to the network biology of diseases and
explained the interrelationships among disease-related
genes and proteins. Recently, the schizophrenia markers,
NRG1 and CACNG2, which were considered function-
ally un-related, were found to be connected via the
ERGG and DRL protein families in PPI network [36].
Furthermore, in our pilot study, a potential schizophre-
nia marker, EXOC4, was identified by analyzing the PPI
network constructed using four published schizophrenic
marker genes [37].
This study constructed PPI networks for schizophrenia,
bipolar disorder, and major depression using abnormally
expressed genes in Brodmann area (BA) 10 of prefrontal
cortex. The “core” functional module of BA10 was also
constructed by the most highly expressed genes in disease
and control samples. Potential disease marker genes and
drug targets were also identified.
Methods
This study constructed PPI networks for post-mortem
prefrontal cortex of schizophrenia, bipolar disorder, and
major depression patients. It focuses only on direct (physi-
cal) interactions among proteins. Genetic interactions
were not investigated. The PPI networks were constructed
based on the hypotheses that (1) the abundance of pro-
teins and mRNAs were positively correlated in brains; (2)
proteins were more likely to interact with proteins which
had similar expression patterns or were more abundant;
and (3) more abundant proteins participated in more
active biological processes.
The research methodology is summarized in Figure 1.
Microarray data series was used to identify genes abnor-
mally expressed in patients’ BA10 of prefrontal cortex.
These genes, together with the brain specific genes, were
used to construct a PPI network for topological analyses.
This network was compared with the PPI networks con-
structed by disease genes mentioned by in published lit-
eratures. The most abundant protein interactions in BA10
were revealed by the most highly expressed genes in the
brain samples to outline the framework of prefrontal cor-
tex biochemistry.
Sources of microarray data
The raw data (CEL files) of microarray data series,
GSE12654, were downloaded from Gene Expression
Omnibus (GEO) and normalized by mas5 [38]. GSE12654
was first published by Iwamoto et al of RIKEN, Japan [39].
GSE12654 is the microarray data of post-mortem human
brain sampled from the BA10 of four groups of people,
including 13 schizophrenia patients, 11 bipolar disorder
patients, 11 major depression patients, and 14 healthy con-
trols [23]. Each group of the three diseases and the control
samples was termed as a “sample group” in this study.
Selection of the most highly expressed genes
The z-scores of genes were calculated within each disease
or control sample group. Each gene had four z-scores—
three for each disease sample groups and one for the con-
trol sample group. The genes with z-scores ≥ 1.96 in ≥
49% samples of a given sample group (e.g. in ≥ 7/13 schi-
zophrenia samples) were defined as the most highly
expressed genes of the sample types. These genes were
likely to encode the most abundant proteins in BA10 of
patients or healthy people.
Selection of tissue-specific “essential” genes for the
healthy BA10 samples
GSE1133 (Human U133A/GNF1H) [40] was downloaded
from the Novartis Research Foundation Gene Expression
Database (GNF). The gcrma-normalized expression value
of a gene in the prefrontal cortex was compared with the
mean expression value of the same gene in all tissues
examined in GSE1133. The genes were defined as pre-
frontal cortex-specific genes, if their expression values in
the prefrontal cortex were > 4 fold higher than the mean
values in all tissues. The genes which were both specific
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score ≥ 1.96 in ≥ 49% samples) in the control sample
group of GSE12654, were defined as the tissue-specific
“essential” genes of healthy BA10.
Selection of abnormally expressed genes in disease
samples
Considering the diverse conditions of post-mortem brain
samples (e.g. pH values), the profiles of subjects (e.g. age,
gender, and use of medication), and the complexity of
disease mechanisms, the microarrays in GSE12654 were
analyzed by 2-tailed t-test. Each disease sample group was
paired with the control sample group in the t-tests. The
genes which expressed abnormally in disease samples
would be detected by the corresponding probes with sig-
nificant changes (P values < 0.01) of signal intensities in
the disease sample groups as comparing to the control.
Construction of PPI networks for mental diseases
The most highly expressed genes and abnormally
expressed genes were located on the human PPI network
by an updated version of POINeT [37] to construct a
query-query PPI (QQPPI) or level 1 PPI (L1PPI) net-
works. The updated version of POINeT contains the
databases listed in Table 1 and has not been published.
QQPPI networks only used the query marker genes as
the nodes and revealed direct interactions among these
queries. L1PPIs also showed the other non-query nodes
directly connecting to the queries. L1PPI network
allowed analysis of an extended network and could reveal
indirect interactions (via common level 1 interactors as
mediators) among query genes.
Topology analysis of PPI networks
To analyse the QQPPI and L1PPI networks, cliques and
centralities were calculated. A clique is a set of genes
(nodes) in which every two genes (nodes) are connected
by a protein interaction (edge). Cliques have been used
successfully to identify protein functional units in PPI
networks [41]. Nodes within cliques are more likely to
form complexes [42]. In this study, cliques with 4 nodes
( c l i q u e - 4 )o ra b o v ew e r ei d e n t ified from PPI networks.
They were searched again s tC O R U M[ 4 3 ]a n dH P R D
[44] for potential protein complexes.
Centrality analyses can assist in identifying significant
proteins (nodes) which have relatively more PPIs (edges)
in a network. The centrality of nodes in the L1PPI net-
work which consisted of the abnormally expressed and
“essential” genes was calculated by CentiBiN [45,46]. The
centrality scores were ranked. The ranks from different
centrality algorithms were fused by summing the ranking
numbers [47].
Gene annotation
T h eh i g h l ye x p r e s s e dg e n e sw e r ec l a s s i f i e di n t og r o u p s
according to the Gene Ontology (GO) terms [48], using
Figure 1 Research methodology
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table parameters for classification stringency were chosen
for the Gene Functional Classification tool as followed - a
Kappa similarity term overlap of 3, a Kappa similar thresh-
old of 0.3, an initial group membership of 3, a final group
membership of 3, and a multiple linkage threshold of 0.5.
The functions of abnormally expressed disease genes
( Pv a l u e<0 . 0 1 )w e r es u m m a r i z e du s i n gt h eF a t i G O +
module of Babelomics 4.2 [50,51]. Functional enrichments
were performed for terms in REACTOME, GO cellular
localisation, GO biological process, or GO molecular func-
tion with default parameters. The functions of genes were
annotated by the Gene List Report in DAVID 6.7 [49].
Comparison with the study of Iwamoto [39]
Different analytical methods of microarray data often
reveal similar but not identical results. The original contri-
butors of microarray GSE12654 were Iwamoto et al who
focused on gender- and age-related genes in their analysis.
The disease genes identified from GSE12654 by Iwamoto
et al [39] were constructed into QQPPI and L1PPI net-
works and compared with ours.
Comparison with data from Phenopedia, GWAS, HGMD,
and GeneRIF
Microarray studies identify changes in gene expression
patterns, whereas gene association studies focus on the
identification of disease-related SNPs and mutations. The
disease markers revealed by these different approaches
were compared with our study.
Phenopedia collect genes which associate with human
diseases by retrieving curated records from PubMed on a
weekly basis since 2001 [52]. The genes which were listed
in Phenopedia as being associated with schizophrenia,
bipolar disorder, and major depression were constructed
into QQPPI and L1PPI networks, and compared with the
network constructed by the abnormally expressed disease
genes. The disease-associated SNPs and mutations which
were listed in A Catalog of Published Genome-Wide Asso-
ciation Studies (GWAS) [53] or The Human Genome
Mutation Database (HGMD) [54] were also compared
with our findings.
In addition, dopamine, GABA, and glutamate are three
of the most significant chemicals known to affect the
symptoms of the studied mental diseases. The association
of abnormally expressed and tissue-specific “essential”
genes with dopamine, GABA, and glutamate were
searched in GeneRIF.
Results
BA10 of the prefrontal cortex is believed to be responsible
for cognition, which is a function disrupted often in
patients of psychiatric diseases [55,56]. By analyzing the
microarrays of human BA10 samples, this study identified
potential disease marker genes and drug targets of schizo-
phrenia, bipolar disorder, and major depression. Addition-
ally, a “core” functional module was constructed using the
genes which were not only highly expressed in both dis-
ease and control samples, but also topologically significant
in the PPI networks.
Abnormal gene expression in the prefrontal cortex of
schizophrenia, bipolar disorder, and major depression
patients
The differential expression of genes in the BA10 samples
was investigated by t-tests comparing the signal intensities
of corresponding probes in microarrays for the disease
and control samples. The genes of which the correspond-
ing probes had P values < 0.01 were defined as abnormally
expressed and proposed as disease markers. These disease
markers, together with the tissue-specific “essential” genes,
were used as queries to reveal the QQPPI network shown
in Figure 2. The functions of query genes are listed in
Additional file 1 (titled ‘Abnormally expressed disease
genes and functions’). The genes and P values of corre-
sponding probes are listed in Additional file 2, 3, and 4
(titled ‘Abnormally expressed genes and corresponding
probe IDs and P values in t-tests’ for ‘schizophrenia’, ‘bip-
olar disorder’,a n d‘major depression’, respectively).
The abnormally expressed genes could be classified into
13 groups according to their functional annotations as
detailed in Additional file 5 (titled ‘GO functional classifi-
cation for abnormally expressed genes’). They participated
in transcription, translation, cytoskeleton, neuron differen-
tiation, ATP-binding, cellular transportation, and many
other biological processes. Using the functional enrich-
ment tool FATIGO+, a few functional terms were found
to be more abundant in our abnormally expressed proteins
of BA10 than in the entire proteome encoded by human
genome. Table 2 lists the GO biological processes which
were enriched in our abnormally expressed genes. The
results of functional enrichment analyses for GO cellular
Table 1 PPI databases used for constructing PPI networks in this study
Database Version or downloading date Number of recorded PPIs
HPRD Release 9 39194
BioGRID 3.1.70 356818
IntACT 2010-12-06 146227
NCBI gene interactions 2010-12-06 585982
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Table 2 Functional enrichment analysis for abnormally expressed disease markers
GO: biological process Go term
ID
Genes with this term
Translation GO:0006412 DHX29, EIF4G1, FAU, GSPT1, KRT7, MAZ, RPL10A, RPL17, RPL 18, RPL21, RPL21P119, RPL21P16, RPL21P39,
RPL21P80, RPL21P93, RPL21P97, RPL22, RPS15A, RPS5, VARS, MRPS12, PABPC4, RPS27A, TOP3A
Transmission of nerve
impulse
GO:0019226 CPNE6, GABARAP, MUSK, POU3F2, VGF, ADORA2A, GRM8, NF1, NMU, PARK2, DLGAP2, GNAI2, HRAS,
NOS1, RPS27A, STX1A, UBB, UBC
Synaptic transmission GO:0007268 CPNE6, GABARAP, MUSK, VGF, ADORA2A, GRM8, NMU, PARK2, DLGAP2, GNAI2, HRAS, NOS1, RPS27A,
STX1A, UBB, UBC
Negative regulation of
catalytic activity
GO:0043086 GNAT1, TNNI3, ADORA2A, GRM8, NF1, GNAI2, OXA1L, RPS27A, SH3BP5, TSC2, UBB, UBC
Regulation of synaptic
transmission
GO:0050804 VGF, ADORA2A, GRM8, NMU, PARK2, GNAI2, HRAS, RPS27A, STX1A, UBB, UBC
Translational elongation GO:0006414 FAU, RPL10A, RPL17, RPL18, RPL21, RPL21P119, RPL21P16, RPL21P39, RPL21P80, RPL21P93, RPL21P97,
RPL22, RPS15A, RPS5, VARS, RPS27A
Regulation of
synaptogenesis
GO:0051963 MUSK, RPS27A, UBB, UBC
Polyamine metabolic
process
GO:0006595 ODC1, SLC6A11, OAZ2, SAT1
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are detailed in Additional file 6 (titled ‘FatiGO term
enrichment with P values smaller than 0.01). Enriched
functions can be classified into five groups—(1) neuron
and signal transduction-related, such as neuron projection,
transmission of nerve impulse, synaptic transmission,
synaptogenesis, and signalling by NGF; (2) cytoskeleton;
(3) gene expression, such as translation and ribosomes; (4)
metabolisms of lipids, lipoproteins, proteins, polyamines,
and sugars (diabetes); and (5) stresses, such as influenza
infection. The enrichment of neuron and signal transduc-
tion-related functions was expected. Abnormality in trans-
lation-related genes has been observed in previous studies
[39,57]. Abnormality in cytoskeleton genes could lead to
disrupted cellular mobility of Golgi apparatus, which has a
place in neuron signal transduction [58-61]. Previous stu-
dies have also shown abnormal expression of ATP-related
or mitochondrial genes [20,22,62-64]. The enriched meta-
bolism functions can be further evidences of abnormal
energy conversion in patients’ prefrontal cortex. The rela-
tionship to influenza infection can be explained as biotic
stress; and stresses have often been reported as inducers of
mental diseases [65-67].
The ranks of centrality were calculated by various algo-
rithms and are listed in Additional file 7 (titled ‘Centrality
analysis of abnormally expressed genes in QQPPI net-
work’). The top ranked nodes are summarised in Table 3.
Proteins which rank higher in centrality analyses of PPI
networks usually have more crucial biological functions
[ 6 8 ] .T h et o pr a n k e dn o d e s( e . g .U B C ,U B B ,a n dA C T B )
were therefore proposed as having critical roles in disease
mechanisms. Only three clique-3s were found (data not
shown). Clique-4 or above was not identified as a result of
the looser network formed by the abnormally expressed
genes (Figure 2) in comparison with the tightly knitted
network formed by the highly expressed genes (Figure 3).
The disease marker genes identified through different
analytical approaches were connected in PPI networks
T h em i c r o a r r a yd a t as e r i e su s e di nt h i ss t u d yh a sb e e n
analysed by the original contributors, Iwamoto et al [39].
In the studied mental diseases, Iwamoto et al revealed
down-regulation of receptor-, transporter-, and channel-
encoding genes; and up-regulation of transcription-,
translation-, stress- and molecular chaperon-related
genes [39]. Although the genes identified in our studies
were not identical to the findings of Iwamoto et al,t h e y
fall into similar functional categories. Although few of
our disease markers had direct protein interactions with
the ones described in Iwamoto et al [39], many had
Table 3 Centrality analysis of PPI network
Gene
symbol
Disease(s) or essential
gene*
Gene function(s) Sum of
ranks**
UBC S ￿ ubiquitin C 7
ACTB S ￿ actin, beta 15
UBB S ￿ ubiquitin B 29
APP E ￿ amyloid beta (A4) precursor protein 32
FOS S ￿ v-fos FBJ murine osteosarcoma viral oncogene homolog 51
HSPA4 S ￿ heat shock 70kDa protein 4 54
PARK2 SD ￿ Parkinson disease (autosomal recessive, juvenile) 2, parkin 67
SYK B ￿ spleen tyrosine kinase 97
TUBB2A E ￿ tubulin, beta 2A 117
TSC2 S ￿ tuberous sclerosis 2 127
UCHL1 E ￿ ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 217
MARK3 S ￿ MAP/microtubule affinity-regulating kinase 3 236
RPS27A S ￿ ribosomal protein S27a pseudogene 12; ribosomal 355
DNM1 E ￿ dynamin 1 476
IRS2 E ￿ insulin receptor substrate 2 497
GNAI2 S ￿ guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 519
SMARCC2 B ￿ SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily
c, member 2
525
HRAS S ￿ v-Ha-ras Harvey rat sarcoma viral oncogene homolog 527
SAT1 S ￿ spermidine/spermine N1-acetyltransferase 1 529
CRKL B ￿ v-crk sarcoma virus CT10 oncogene homolog (avian)-like 531
The L1PPI network (not shown) was constructed by abnormally expressed disease markers, tissue-specific “essential” genes
*The listed genes were found abnormally expressed in samples of schizophrenia (S), bipolar disorder (B) or major depression (D), or were tissue-specific
“essential” (E) genes.
**The sum of centrality ranks calculated using various centrality algorithms for the disease and “essential” genes shown in Figure 2.
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interactors) in between. Taking bipolar disorder as an
example, there was only one gene listed in both Iwamoto
et al and this study as a disease marker; only two of our
abnormally expressed genes for bipolar dirorder had
direct interactions (PPIs) with two bipolar disorder mar-
kers of Iwamoto et al.H o w e v e r ,o u rm a r k e r so fb i p o l a r
disorder shared 120 level 1 interactors with the bipolar
disorder markers of Iwamoto et al [39].
Similar results were observed in the data of Phenopedia
as summarized in Table 4. For schizophrenia, bipolar dis-
order, and major depression, there were only 11, 5, and 5
genes, respectively, that were listed both as disease genes
in Phenopedia and as our disease markers. Interestingly,
there were many PPIs formed between the Phenopedia
disease genes and our abnormally expressed genes for
schizophrenia, bipolar disorder, and major depression as
illustrated in Additional file 8, 9, and 10 (titled ‘Interrela-
tionship between Phenopedia and abnormally expressed
genes’ in ‘schizophrenia’, ‘bipolar disorder’,a n d‘major
depression’, respectively). The names of these disease
genes are listed in Additional file 11 (titled ‘Comparison
of disease genes listed in Phenopedia, HGMD, and
GWAS’). The diseases associated SNPs and mutations
Figure 3 a) QQPPI constructed by highly expressed genes in disease and control samples; b) The “core” functional module
Table 4 Comparison to the disease genes listed in Phenopedia
Record type Schizophrenia Bipolar disorder Major depression
Disease genes in Phenopedia (P) 1001 722 226
Abnormally expressed genes (T)* 110 100 44
Both P and T (shared nodes) 11 5 1
PPIs between P and T 252 73 11
* Genes with P values < 0.01 in t-tests
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pared with the abnormally expressed genes identified in
this study and listed also in Additional file 8.
Furthermore, dopamine, GABA, and glutamate are criti-
cal chemicals affecting the symptoms of schizophrenia,
bipolar disorder, and major depression. Genes which were
described in GeneRIF as involving in the biochemistry of
these chemicals are listed in Table 5. This data was con-
sidered as the indirect evidence to the association of genes
to the studied mental diseases.
The highly expressed genes and the most abundant
protein interactions in the prefrontal cortex
In order to identify the most abundant protein interactions
in BA10, the PPI network of highly expressed genes were
constructed for schizophrenia, bipolar disorder, major
depression, and healthy control samples as illustrated in
Figure 3a. Many PPIs were shared by two or more of the
diseases. Disease-associated SNPs, mutations, and GO
functional classes were identified for each gene and
labelled as shown in Figure 3a.
In this PPI network, there were one clique-5 and sev-
eral clique-4s that tightly knitted into a sub-network con-
taining 12 genes as shown in Figure 3b. These 12 genes
in the BA10 cliques encode four heat shock proteins
(HSPA8, HSP90AA1, HSPD1, HSP90AB1), the tubulin
protein (TUBA1A), the ubiquitin protein (UBC), the
actin-binding cytoskeleton protein (SPTAN1), beta-actin
(ACTB), the energy generating glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), translation elongation
factor (EEF1A1), signal transduction protein (YWHAZ),
and amyloid beta (A4) precursor protein (APP). This
sub-network of 12 highly expressed and topologically sig-
nificant genes was proposed as the “core” functional
module of BA10 for both patients and healthy people.
Discussion
This study combined data of quantitative transcriptomics
and PPIs for statistical and topological analyses. New
disease marker genes and potential drug targets were
revealed. Shared disease mechanisms, although hypothe-
tical at the present, were proposed based on common
marker genes and interconnecting PPIs to explain the
shared symptoms among diseases. A “core” functional
module of BA10 was also proposed.
Disease markers and potential drug targets
The genes which had P values < 0.01 in our t-tests were
defined as abnormally expressed in disease samples. These
genes were proposed as disease marker genes and con-
structed into a PPI network as illustrated in Figure 2.
Previous studies have shown that the probes (and the
genes which they represented) with lower P values
appeared as more effective clustering features for separat-
ing the disease samples from the controls in hierarchical
clusters (unpublished data). The observation suggested
that genes with lower P values are more important dis-
ease markers.
The genes with the lowest P values in our t-tests were
not well-studied genes. SBNO2 was a gene of which the
probe had the lowest P value in the t-test comparing schi-
zophrenia and control samples. SBNO2 has a strawberry
notch homolog in fruit fly. The gene is involved in the
anti-inflammatory signalling pathway [69]. It has also been
associated with type 2 diabetes mellitus, of which shared
many disease genes with mental diseases [52,70]. SEC24C
was a gene of which the probe had the lowest P value in
the t-test comparing bipolar disorder and control samples.
SEC24C encodes a protein which may be involved in ER
to Golgi vesicular transportation [71]. It has been asso-
ciated another mental disease, Alzheimer’s disease [52].
SRRT was a gene of which the probe had the lowest P
value in the t-test comparing major depression and control
samples. SRRT is possibly involved in transcriptional regu-
lation and RNA metabolism as it is a homolog to an
Arabidopsis serrate RNA effector [72]. Apart from this
study, SBNO2, SEC24C and SRRT have never been asso-
ciated with schizophrenia, bipolar disorder, or major
depression; these genes did not form PPI with any of our
abnormally expressed marker genes, either.
There appeared a weak negative correlation between
the P values of a gene (probe) and its centrality ranks in
Table 5 Genes which participated in the biochemistry of
GABA, glutamate, or dopamine
Gene Symbol GABA Glutamate Dopamine
APP ++ +
GABBR2 ++
GABBR1 ++
SLC12A5 +
GABARAP +
SLC1A3 +
NOS1 +
GRM8 +
GLUL +
UCHL1 +
SYNGR3 +
STXBP1 +
STX1A +
SNCB +
PRKAR1B +
PARK2 +
IGF1 +
GPR143 +
EPB41L1 +
CRYAA +
ADORA2A +
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have also been shown to rank higher than less impor-
tant proteins in centrality analyses [68,73]. Interestingly,
the nodes which ranked highest in the centrality studies
were mostly schizophrenia markers as listed in Table 3.
The top ranked genes in centrality analysis, UBC,
ACTB, and UBB, were all abnormally expressed in schi-
zophrenia samples. UBC and UBB encode the polyubi-
quitin precursors. ACTB encodes the beta-actin protein.
The roles of these proteins in mental disease mechan-
isms are not clear. None of these three genes have been
associated with any mental disease; but UBC has been
associated also with type 2 diabetes mellitus [70].
Schizophrenia samples had the largest number of abnor-
mally expressed genes, and major depression had the few-
est. The above observations aligned with the most severe
and complex symptoms of schizophrenia in comparison to
the other two diseases; major depression encompassed the
least of symptoms. All three disorders may show signs of
psychosis, but symptoms such as hallucinations and pov-
erty of speech are usually only seen with schizophrenia.
The delusions associated with bipolar disorder and major
depression is usually the milder “mood-congruent” delu-
s i o nc o n t r i b u t i n gt ot h eo v e r l yp o s i t i v eo rn e g a t i v es e l f
perceptions of manic or depressive patients. Whereas the
delusions occur with schizophrenia can be completely
implausible and “bizarre”. The additional symptoms of
schizophrenia may be caused by additional aberrations of
genes. It must be noted, however, that few evidences are
available to support or clarify this assumption.
Shared disease mechanisms
The three studied mental diseases are genetically related
and share disease genes [16,17]. Each disease may have
malfunctions in multiple biological pathways, and the
same malfunctions may occur in multiple diseases [74].
There are also increasing numbers of evidences which
indicate correlations in genetic risks for schizophrenia
and bipolar disorder [75-79].
A few genes were found to be abnormally expressed in
more than one disease in this study. As shown in Figure 2,
MUSK, which encodes a protein responsible for the
assembly of receptors in post-synaptic neuromuscular
junctions, was abnormally expressed in samples of bipolar
disorder and major depression [80,81]. PARK2, a gene of
unknown function associated with related phenotypes
such as Parkinson disease, nerve degeneration, cognition
disorders, visual perception, attention, and memory, was
abnormally expressed in schizophrenia and major depres-
sion [52,82-84]. AP4M1, which encodes a subunit of AP-4
complex responsible for transportation of proteins from
Golgi, was abnormally expressed in schizophrenia and
bipolar disorder [52,85]. Many of the genes were also
found to be highly expressed in more than one disease as
shown in Figure 3a.
One might hypothesize that the shared genes are the
reasons for shared symptoms— the abnormal expression
of MUSK may cause the depression of bipolar disorder
and major depression; PARK2 may cause the psychosis
symptoms such as delusions, avolition, blunted effect, aso-
ciality, and cognitive dysfunction, which are commonly
seen with varying severities in both schizophrenia and
major depression; AP4M1 may cause the psychosis symp-
toms such as the less “bizarre” forms of delusions and rest-
lessness sometimes observed in both schizophrenia and
bipolar disorder. These hypotheses are far from being con-
clusive. Further researches such as mutant studies in ani-
mal models, genetic association studies, and gene and
protein expression analyses are required to better explain
the observed phenomenon of overlapping PPI network of
the mental diseases. Unfortunately, as symptoms such as
hallucinations and delusions are uniquely human, the
exact roles of disease-associated genes play in mental dis-
ease mechanisms are difficult to be studied using mutant
model animals [86].
The centrality ranks of MUSK, PARK2, and AP4M1
might indicate the divergence or similarity of the studied
mental diseases, if phenotypical similarities were posi-
tively correlated with similarities in disease mechanisms.
In the PPI network constructed using 3550 human dis-
ease genes retrieved from OMIM Morbid Map, shared
genes were more central than disease-specific genes, and
the genes shared by phenotypically similar diseases are
less central than the ones shared by phenotypically diver-
gent diseases [73]. AP4M1 ranked the lowest in centrality
among the three genes as shown in Fig. 2; PARK2 ranked
the highest. We might deduce that the disease mechan-
isms of schizophrenia and bipolar disorder are most simi-
lar among the three studied diseases; and the disease
mechanisms of schizophrenia and major depression are
most diverged.
“Switchboards” in PPI sub-networks of psychiatric
diseases
Apart from shared marker genes, marker genes of multi-
ple diseases sometimes interact with the same critical
nodes. These critical nodes were designated as “switch-
board” nodes to describe their place in interconnecting
PPIs of different diseases. The “switchboards” usually
ranked higher in centrality analyses, suggesting they are
more “essential” and effect diverged ranges of pheno-
types. The abnormalities of different protein interactions
with the same gene may explain the relevant but different
symptoms of the studied diseases.
In the schizophrenia PPI network shown in figure 2,
the “switchboard” APP interacted with the abnormally
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Page 9 of 15expressed ACTB and FOS. APP was a tissue-specific
“essential” gene, which encodes a highly expressed beta-
amyloid precursor protein. ACTB encodes the beta-
actin, which is responsible for cellular structure and
(neuron signal) mobility [87-89]. FOS is likely to associ-
ate with cell differentiation, apoptotic cell death, and
depression-related diseases such as bulimia and anorexia
[52,90]. In bipolar disorder, APP interacted with the
abnormally expressed F12. F12 encodes a coagulation
factor which circulates in blood as zymogen. Mutations
in F12 may prolong whole-blood clotting time; and the
gene has been associated with type 1 and 2 diabetes mel-
litus [52,91-93]. In major depression, APP interacted
with the abnormally expressed NF1. NF1 encodes a neu-
rofibromin responsible for signal transduction, and has
been associated with mental retardation and autism
[52,94,95]. APP has been listed in the HGMD as being
associated with schizophrenia [96]. However, the tran-
script of APP was consistently highly abundant in all dis-
ease and control samples. The mutation of APP in
patients might not have affected its transcription.
A “switchboard” can also be a disease gene. For example,
the ubiquitous protein, UBC, was abnormally expressed in
schizophrenia samples and interacted with the maker
genes of schizophrenia (i.e. TSC2, SCNN1A and USP2),
bipolar disorder (i.e. MUSK), and major depression (i.e.
MUSK and FLT3).
The same “switchboard” mechanism was observed in the
network constructed by the most highly expressed genes.
One such example was YWHAZ, which encodes a signal
transduction protein. YWHAZ interacted with 43 nodes
as shown in Figure 3a and was highly expressed in disease
and control samples. The abnormal PPIs (i.e. PPIs of
highly expressed genes that did not occur in the controls)
between YWHAZ and many other proteins were observed
in disease samples. The interaction with NCL was abnor-
mal in schizophrenia, bipolar disorder, and major
depression. The other YWHAZ abnormalities were the
interactions with RNPS1 and LGALS1 in schizophrenia;
the interactions with MYCBP2, PRDX1 or TP1l in bipolar
disorder; the interactions with RPLP2 and VIM in major
depression; and the interactions with RPLP0 in both schi-
zophrenia and major depression.
The “core” functional module
We proposed that the 12 genes in the clique-5 and -4s in
PPI constructed by the highly expressed genes were cen-
tral to the functioning of BA10 (Figure 3a and b). These
nodes were the ones with the highest ranks in the cen-
t r a l i t ya n a l y s i so fP P In e t w o r ko fh i g h l ye x p r e s s e dg e n e .
A few genes, such as UBC and ACTB, were also highly
ranked in the centrality analysis of the abnormally
expressed PPI network as listed in Table 3. Many of
these genes encode members of important protein com-
plexes as summarised in Table 6. They were mostly tis-
sue-specific “essential” genes and highly expressed in all
three studied mental diseases as well as healthy control.
The nodes in cliques were sometimes involved in biologi-
cal processes which were disrupted in schizophrenia,
bipolar disorder, or major depression.
Teams of disease marker genes
The abnormally expressed genes identified in this study
were compared with published disease associated genes
from previous analysis of the same data series (GSE12654),
Phenopedia, GWAS, and HGMD. Although few genes
were consistently identified in diseases by different groups
of researchers, many of these genes were found to form
QQPPIs or share the same level 1 PPI interactors as
shown in Table 4 and Additional file 8, 9, and 10.
Table 6 Cliques in the PPI network constructed by highly expressed genes in disease and control samples
List of clique-4 Protein complex
HSPA8 HSP90AA1 APP YWHAZ ￿ Nil
HSPA8 HSP90AA1 APP ACTB ￿ Amyloid beta protein oligomer (PMID:15834427)
HSPA8 HSP90AA1 ACTB YWHAZ ￿ APP-FE65-LRP complex (PMID:15115822)
HSPA8 APP ACTB YWHAZ ￿ APP-TIMM23 complex (PMID:16943564)
HSP90AA1 APP ACTB YWHAZ ￿ APP-TOMM40 complex (PMID:16943564)
HSP90AA1 ACTB YWHAZ TUBA1A ￿ Emerin architectural complex (PMID:17620012)
GAPDH HSP90AB1* ACTB YWHAZ ￿ Emerin complex 25 (PMID:17620012)
GAPDH APP ACTB YWHAZ ￿ Emerin-actin-NMI- (PMID:alphaII) spectrin complex (PMID:17620012)
HSPA8 ACTB UBC* YWHAZ ￿ Kinase maturation complex 1 (PMID:14743216)
HSP90AB1* ACTB SPTAN1 YWHAZ ￿ P2X7 receptor signaling complex (PMID:11707406)
HSP90AA1 HSPD1 ACTB YWHAZ ￿ Profilin 2 complex (PMID:9463375)
EEF1A1* ACTB UBC* YWHAZ ￿ Profilin 2 complex (PMID:9463375)
APP ACTB SPTAN1 YWHAZ ￿ Nil
The protein complexes which may contain nodes within these cliques-4s are listed.
* This protein was not documented as a member of the suggested protein complex.
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patients, disease genes can become defected due to var-
ious abnormalities and lead to the same symptoms. Each
research approach may only detect a sub-set of abnorm-
alities, such as mutation, significant changes in gene
expression, or smaller changes in gene expression.
Besides, only a snapshot of transcript abundance can be
detected in post-mortem brain samples. The proteins
were likely to work in teams—the failure of any team
members at any given time may similarly disrupt the par-
ticipating biological process and cause similar pheno-
types. A protein team may be a set of proteins which
have direct physical interactions, such as QQPPIs, or via
a common protein, such as in the more extended L1PPIs.
A more stringent definition of a protein team can be a
set of proteins which form cliques. The teams may also
be defined by genetic interactions, although it may not be
applicable for human samples which cannot have syn-
thetic lethal experiments; nonetheless, redundancy or
overlapping of gene functions may be speculated with
sequence homology.
Network medicine
Psychiatric drugs may be developed based on the con-
cepts of network medicine. Network analysis of disease
genes have been shown to significantly accelerate the
trials for new treatments [97].
Combining drugs to target the largest number of disease
genes in a PPI network, while avoiding non-disease genes
to avoid side effects, has been shown to create effective
new treatments for complex diseases [98]. Besides, topolo-
gically significant non-markers can also be potential drug
targets so that the “switchboard” gene APP and its neigh-
bouring nodes were proposed as potential drug targets
[99]. APP is a cell surface receptor and trans-membrane
precursor which can be cleaved to from peptides. The
exact function of APP was not clear, but its roles in cellu-
lar signalling neuronal adhesion and positioning in cortical
layers have been observed in mice models [100,101]. APP
has also been reported to participate in the biochemistry
of GABA, dopamine, and glutamate (Table 5), which are
all known to have significant places in the symptoms of
the studied mental diseases. Abnormal accumulation of
APP protein has long been associated with Alzheimer’s
disease [102]. The polymorphism of APP has also been
associated with schizophrenia as listed in HGMD,
although its gene expression was not significantly different
in disease samples of this study. The gene’s association
with cognition, dementia, and type 2 diabetes mellitus
have also been mentioned [52]. The other “switchboards”,
including UBC and YWHAZ, and their neighbouring
nodes can also be potential targets for developing new
treatments.
Limitations of the research methods
This study analysed the disease mechanisms by consider-
ing the interactions of the proteins and employing topo-
logical analyses. However, the extensiveness of PPI
subnetworks was limited by the availability of PPI
recorded in the PPI databases listed in Table 1. Markers
whose PPI data were not recorded in databases would be
excluded in the proposed PPI networks. The incomplete
human PPI network could lead to incomplete PPI net-
work for the disease samples; it could also bias the topo-
logical analyses. The significance of disease markers was
therefore evaluated by both t-tests and centrality ana-
lyses. Besides, abnormalities such as deformed protein
structures were not observable in this study. This study
only proposed disease markers which can be detected by
examining the transient abundances of mRNAs. The
functions of many disease marker genes were speculated
by homologous genes in other model organisms and
required confirmation.
Conclusions
By identifying abnormally expressed genes in post-mor-
tem brain samples of mental disease patients, several dis-
ease marker genes were proposed for schizophrenia,
bipolar disorder, and major depression. The disease mar-
kers were constructed into PPI networks and analysed by
topological theories.
A few genes were shared among the studied diseases,
such as MUSK, PARK2, and AP4M1. They are evidences
of shared disease mechanisms. The studied diseases also
shared disease genes with the other mental diseases, such
as Alzheimer’s and Parkinson, and metabolic diseases,
such as type 1 and 2 diabetes mellitus. The research
methodology of this study may be applied to expand our
investigations to related diseases. Genes with higher P
values, ranked lower in centrality analyses and not shared
among diseases are proposed as more effective disease
marker genes; the abnormal expression of these genes
are more likely to be unique to a specific disease.
Nevertheless, disease markers which ranked higher in
centrality analyses, interacted with the “switchboards”,o r
were members of the “core” functional module, were con-
sidered to have more “essential” roles in the disease
mechanisms. These genes included SBNO2, CEACAM5,
AKAP1, UBC, ACTB, UBB, and FOS for schizophrenia;
SEC24C, PGLYRP1, ARHGAP4, RPL22, SLC6A11, and
SYK for bipolar disorder; and SRRT, PARK2, LILRA4,
STK17A, IGFBP2, and NF1 for major depression. These
markers, together with the “switchboards” such as APP,
UBC, and YWHAZ, were proposed as targets for drug
development.
The three studied mental diseases showed aberrations
in common biological processes. Most of the disease
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been previously proposed as being related to the three
studied mental diseases. Based on published data and the
r e s u l t so ft h i ss t u d y ,i tm i g h tb es a i dt h a tt h es t r e s s
responses, cellular signal transduction, neuron cell differ-
entiation and aging, energy metabolism, and translation
were dysfunctional in patients suffering schizophrenia,
bipolar disorder, or major depression. However, we are
still far from drawing a clear picture of the molecular
biology of patients’ brains. Extensive studies are still
required for establishing the disease mechanisms.
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